Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a simple, noninvasive hair counting method used in a hair growth prevention trial, assessing its reliability and validity.

This study presents a detailed overview of lymphatic vessel development and highlights the role of abnormal lymphangiogenesis in various diseases, suggesting that targeting lymphangiogenic factors may improve treatment strategies.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This review suggests that platelet-rich plasma shows potential for improving alopecia areata and skin rejuvenation, but more research is needed as evidence primarily supports short-term outcomes in orthopaedic applications.

This review examines the potential of regulatory T cell-based therapies to transform treatment across various medical specialties by promoting immune tolerance and tissue repair, but it reports no new clinical results.

This study found that Sinja Valley residents possess traditional knowledge of 13 edible oil-producing plant species, yet this knowledge is at risk due to sociocultural changes. Despite its benefits, including treating disorders like gastritis, use of indigenous oils is declining as commercial products become prevalent.

Among families with pediatric brain disease, this study identified over 200 novel genetic causes, revealing potential treatment points using drug repurposing or nutritional supplementation.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study highlights the role of platelets in immune interactions and severe adenovirus infection, noting that activated platelets have a shorter lifespan. Results suggest potential for developing therapies targeting platelet senescence and immunologic mechanisms.

This study found that storing horse hair follicles in RNAlater® at cool or room temperature for up to a week did not affect RNA integrity, suggesting it allows for flexible sample transport without immediate freezing.

This study found that γδ T cells play a role in regulating stromal behavior, influencing the composition and vascularity of fibrotic tissues during the foreign body response.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This article discusses the potential association between the use of hair oils and the exacerbation of seborrheic dermatitis in black patients, suggesting more research is needed to understand their impact.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study is the first to report that apremilast may be effective in treating refractory lichen planopilaris and frontal fibrosing alopecia, though some patients experienced adverse effects leading to discontinuation.

Covers common skin issues in kids, their diagnosis, treatment, and need for specialist care.

This report suggests that recombinant human erythropoietin use may be linked to alopecia in Southeast Asian women with chronic renal failure.

This study introduces stem cell activity as a key factor influencing the effects of IFN-γ and TGF-β1 on autoimmune disease dynamics, showing that varying cytokine levels can modulate stem cell activity and immune privilege, impacting tissue regeneration and disease flares.

This review reports that pregnancy-specific dermatoses, including AEP, PEP, ICP, and PG, present overlapping clinical features and can significantly impact fetal outcomes, particularly ICP and PG, which are linked to preterm birth and stillbirth.

In this study, RNA integrity in horse hair follicles stored at various conditions in RNAlater® was maintained, showing that storing them at cool or room temperature for up to a week does not compromise RNA quality or concentration.

This review discusses the potential role of androgens in COVID-19's pathophysiology and their possible link to hair disorders, but reports no new clinical results.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

This review discusses advancements in radiation therapy and chemotherapy making these cancer treatments more precise, convenient, and less toxic, but reports no new clinical results.

The meeting highlighted the genetic basis of female pattern hair loss and various skin health insights.

This review concluded that near-infrared and red light photobiomodulation shows potential for certain ocular conditions like age-related macular degeneration and dry eye disease, but clinical evidence is still mixed and insufficient to establish it as a standard therapy.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.